DDInter1696 DDInter1676
Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Solifenacin {u} (Compound) resembles {v} (Compound) Mequitazine
Solifenacin {u} (Compound) resembles {v} (Compound) Benazepril
Solifenacin {u} (Compound) binds {v} (Gene) CHRM4
Solifenacin {u} (Compound) palliates {v} (Disease) multiple sclerosis
Solifenacin {u} (Compound) is included by {v} (Pharmacologic Class) Cholinergic Muscarinic Antagonists
Solifenacin {u} (Compound) causes {v} (Side Effect) Atrial fibrillation
Solifenacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Solifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Degarelix
Solifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troglitazone
Solifenacin {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Solifenacin (Compound) resembles Mequitazine (Compound)
Solifenacin (Compound) resembles Benazepril (Compound)
Solifenacin (Compound) binds CHRM4 (Gene)
Solifenacin (Compound) palliates multiple sclerosis (Disease)
Solifenacin (Compound) is included by Cholinergic Muscarinic Antagonists (Pharmacologic Class)
Solifenacin (Compound) causes Atrial fibrillation (Side Effect)
Solifenacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone
Solifenacin may lead to a major life threatening interaction when taken with Potassium chloride